<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652769</url>
  </required_header>
  <id_info>
    <org_study_id>07/0156</org_study_id>
    <nct_id>NCT00652769</nct_id>
  </id_info>
  <brief_title>A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)</brief_title>
  <acronym>BOOST</acronym>
  <official_title>A Randomized Controlled Trial of Endobronchial or Endoscopic Ultrasound as a First Test in the Diagnosis and Staging of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Middlesex University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barnet and Chase Farm Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Whittington Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College London Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the UK, staging of lung cancer is time consuming (taking on average more than 3 weeks),
      costly and inaccurate in up to 20% of cases. The investigators wish to determine whether
      using the newer techniques of endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS)
      improves lung cancer staging. The investigators' hypothesis is that EUS (endoscopic
      ultrasound) or EBUS (endobronchial ultrasound guided transbronchial needle aspirate) as a
      first test after CT scan in the diagnosis and staging of lung cancer will result in a
      reduction in the time from first outpatient appointment to treatment decision, a reduction in
      the total number of scans and investigative operations, fewer outpatient attendances and a
      reduction in healthcare costs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from first outpatient appointment to decision to treat</measure>
    <time_frame>1 - 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The healthcare costs for diagnosing and staging lung cancer</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of tests and outpatient visits a patient requires to be diagnosed and staged with lung cancer</measure>
    <time_frame>1 - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of lung cancer patients that are diagnosed and staged with a single test after CT scan</measure>
    <time_frame>1 - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time from first outpatient appointment to treatment</measure>
    <time_frame>1 - 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of futile thoracotomies</measure>
    <time_frame>1 - 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Bronchogenic Carcinoma</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endobronchial or Endoscopic Ultrasound</intervention_name>
    <description>Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>EBUS: Olympus Keymed BF-UC260F-OL8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy</intervention_name>
    <description>Investigations will be determined by the multi-disciplinary team responsible for the patient</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients suspected of lung cancer on CT scan

          -  Written informed consent

          -  Able to tolerate bronchoscopy and thoracic surgery

        Exclusion Criteria:

          -  Evidence of severe or uncontrolled systemic disease that makes it undesirable for the
             patient to participate in the trial

          -  Any disorder making reliable informed consent impossible

          -  Patients with extra-thoracic disease, supraclavicular lymphadenopathy or pleural
             effusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Spiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy College London NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sam Janes, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neal Navani, MD</last_name>
    <role>Study Director</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnet General Hospital</name>
      <address>
        <city>London</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whittington Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>N19 5NF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Herder GJ, Verboom P, Smit EF, van Velthoven PC, van den Bergh JH, Colder CD, van Mansom I, van Mourik JC, Postmus PE, Teule GJ, Hoekstra OS. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax. 2002 Jan;57(1):11-4.</citation>
    <PMID>11809983</PMID>
  </reference>
  <reference>
    <citation>Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA; American College of Chest Physicians. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):202S-220S.</citation>
    <PMID>17873169</PMID>
  </reference>
  <reference>
    <citation>Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F; American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):178S-201S.</citation>
    <PMID>17873168</PMID>
  </reference>
  <reference>
    <citation>De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, Waller DA, Lerut T, Weder W. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007 Jul;32(1):1-8. Epub 2007 Apr 19.</citation>
    <PMID>17448671</PMID>
  </reference>
  <reference>
    <citation>Janes SM, Spiro SG. Esophageal endoscopic ultrasound/endobronchial ultrasound-guided fine needle aspiration: a new dawn for the respiratory physician? Am J Respir Crit Care Med. 2007 Feb 15;175(4):297-9.</citation>
    <PMID>17277288</PMID>
  </reference>
  <reference>
    <citation>Navani N, Spiro SG, Janes SM. Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound. Nat Rev Clin Oncol. 2009 May;6(5):278-86. doi: 10.1038/nrclinonc.2009.39. Review.</citation>
    <PMID>19390554</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Sam Janes</investigator_full_name>
    <investigator_title>Reader in Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Cancer</keyword>
  <keyword>Staging</keyword>
  <keyword>Endobronchial</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Endoscopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

